Tech Track 100

After completing a PhD at Oxford, chief executive Ryan Cawood, 36, set up Oxford Genetics with Leonard Seymour, 62, in 2011. Now named Oxgene, its technology platforms are used to accelerate the discovery, development and manufacture of cell and gene therapies. It has redeployed some of its technologies to develop a potential Covid-19 vaccine, and to discover antibodies that could help neutralise the virus. Its scientists are collaborating with Oxford-based The Native Antigen Company to scale up the manufacture of Covid-19 antigens — molecules that stimulate the development of antibodies. Sales reached £6m this year, with existing investors Mercia Asset Management participating in a further £3m investment round in May.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2020
Rank19
CompanyOXGENE
ActivityBiotechnology
LocationOxford
Average 3 year sales growth126.48%
Latest sales £000s*6,002
Staff85
Founded2011
Websitewww.oxgene.com

If applicable:

* supplied by company † annualised figure